Incyte Corp INCY:NASDAQ

Last Price$88.07Cboe Real-Time Last Sale as of 9:56AM ET 9/28/20
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+1.52(1.76%)
Bid (Size)$88.07 (34)
Ask (Size)$88.24 (100)
Day Low / High$87.42 - 88.47
Volume58.4 K
  • Latest Stories
  • Commentary and Analysis
Market Chatter: White House Exploring Options to Offset Medicare's Exclusion to Cover COVID-19 Vaccine: WSJ
1:25PM ET 9/21/2020 MT Newswires

White House officials are exploring options that would make a COVID-19 vaccine free to all Americans despite Medicare's exclusion of drugs approved under...

MacroGenics Achieves $15 Million Milestone Payment Under Retifanlimab Collaboration With Incyte
11:24AM ET 9/21/2020 MT Newswires

MacroGenics (MGNX) said Monday it achieved a milestone payment of $15 million under its collaboration and license agreement with Incyte (INCY) for...

Eli Lilly and Incyte Get Positive Opinion From European Medicines Agency's CHMP for Baricitinib to Treat Atopic Dermatitis
10:52AM ET 9/18/2020 MT Newswires

Eli Lilly and Company (LLY) and Incyte (INCY) said Friday they received a positive opinion from the European Medicines Agency's Committee for Medicinal...

Incyte Releases Positive Results of Phase 2 Study of Cancer Drug Retifanlimab
6:27AM ET 9/18/2020 MT Newswires

Incyte (INCY) on Friday released results of a phase 2 study of retifanlimab in previously treated patients with advanced squamous cell carcinoma of the...

Eli Lilly's COVID-19 Combination Trial Meets Primary Endpoint of Lowering Recovery Time; Plans Emergency Use Authorization Filing
2:28PM ET 9/17/2020 MT Newswires

Eli Lilly (LLY) said Thursday initial data from more than 1,000 patients in a COVID-19 treatment trial of baricitinib in combination with Gilead Science's...

Eli Lilly, Incyte Report Positive Data from Trial of Baricitinib, Remdesivir Combination to Treat COVID-19
8:59AM ET 9/14/2020 MT Newswires

Eli Lilly and Company (LLY) and pharmaceutical company Incyte (INCY) reported positive initial data from their COVID-19 treatment trial sponsored by the...

Calithera Biosciences Cancels License Agreement With Incyte
10:05AM ET 9/04/2020 MT Newswires

Calithera Biosciences (CALA) said in a regulatory filing Thursday it is terminating its collaboration and license agreement with Incyte (INCY) from Sept....

Incyte Says Data Showed Positive Overall Response Rate for Tabrecta in Patients With Non-Small Cell Lung Cancer
3:51AM ET 9/03/2020 MT Newswires

Incyte (INCY) said Wednesday data from a phase 2 study of Tabrecta showed positive overall response rates with durable responses among adults with...

Stocks End Mixed, Pressured by Falling Consumer Confidence in August; S&P 500, Nasdaq Rise to New Records
4:29PM ET 8/25/2020 MT Newswires

Stocks ended mixed on Tuesday as consumer confidence unexpectedly fell this month as the world's top economy continues to find a steady path to recovery...

MorphoSys, Incyte Say Monjuvi Added to Cancer Network's Clinical Practice Guidelines for B-cell Lymphomas
4:33AM ET 8/19/2020 MT Newswires

MorphoSys AG (MOR) and Incyte (INCY) said Tuesday that Monjuvi has been added to the National Comprehensive Cancer Network Clinical Practice Guidelines in...